Form 4: Teva CEO Francis Reports Share Transactions

Teva Pharmaceutical Industries CEO Richard D. Francis reported the vesting and sale of ordinary shares, alongside the grant of new restricted share units.

Summary

• Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd., reported transactions involving the company's ordinary shares and restricted share units (RSUs).
• On March 4, 2026, 50,223 ordinary shares were acquired upon the vesting of RSUs.
• Subsequently, 23,393 ordinary shares were sold at a weighted average price of $32.4645 to cover tax withholding obligations related to the RSU vesting.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 14, 2025.
• Following these transactions, Francis beneficially owns 1,148,212 ordinary shares.
• Additionally, Francis was granted 136,736 new restricted share units on March 4, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices and tax management, with no significant positive or negative implications for the company's operational or financial outlook.

Positives

• The grant of 136,736 new restricted share units indicates continued long-term incentive for the CEO, aligning his interests with future company performance.
• The sale of shares was explicitly for tax withholding purposes, which is a common and expected event associated with RSU vesting and not indicative of a discretionary sale.

Negatives

• A net reduction in directly held ordinary shares occurred due to the tax-related sale, although this is a standard practice for RSU vesting.

Risks

• The sale of shares to cover tax obligations reduces the direct beneficial ownership of ordinary shares by the CEO, which is a standard consequence of equity compensation vesting.

Future Outlook

The filing details future vesting schedules for restricted share units granted to the CEO, with tranches vesting annually through March 4, 2030, indicating a long-term incentive structure.

Industry Context

StockSavvy.ai notes that executive share transactions, particularly those related to RSU vesting and tax withholding, are routine events in the pharmaceutical industry and generally do not signal a change in company fundamentals or executive confidence. The adoption of a Rule 10b5-1 plan prior to the transaction demonstrates a pre-planned approach to managing equity compensation.

Comparison to Industry Standards

• Executive compensation structures involving restricted share units and subsequent sales for tax purposes are standard practice across major pharmaceutical companies like Pfizer, Johnson & Johnson, and Novartis.
• The reported transactions align with typical equity compensation management for senior executives in the sector, reflecting common industry benchmarks for executive equity awards and their associated tax implications.

Stakeholder Impact

• Shareholders: The transactions represent routine executive compensation and tax management, with minimal direct impact on the company's overall share structure or value. The CEO's continued equity holdings align his interests with shareholders.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Future vesting of 50,223 restricted share units on March 4, 2027, and March 4, 2028, from the 2024 grant.
• Future vesting of 34,184 restricted share units on March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, from the 2026 grant.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation and tax obligations, specifically the vesting of restricted share units and a subsequent sale to cover taxes. These are standard events and do not indicate any fundamental change in the company's prospects or the CEO's confidence. The adoption of a Rule 10b5-1 plan further reinforces the pre-planned nature of the sale. Therefore, the filing itself does not provide new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this report.

Keywords

Teva Pharmaceutical Industries, TEVA, Richard D. Francis, Form 4, Insider Trading, Restricted Share Units, RSU, Stock Sale, Executive Compensation, Beneficial Ownership, Rule 10b5-1